Molecular pathways of programmed cell death in experimental Parkinson's disease

Parkinsonism and Related Disorders

Volumn 14, Issue SUPPL.2, 2008, Pages

  Vila, Miquel ^a,b,c   Perier, Celine ^b  

^a INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Apoptosis; Bax; BH3 only; Complex I; Mitochondria; Oxidative stress; p53

Indexed keywords

BH3 PROTEIN; CYTOCHROME C; PROTEIN BAX; PROTEIN P53;

APOPTOSIS; ARTICLE; BRAIN MITOCHONDRION; DOPAMINERGIC NERVE CELL; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; NERVE CELL DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS; ELECTRON TRANSPORT COMPLEX I; HUMANS; MITOCHONDRIA; PARKINSONIAN DISORDERS;

EID: 47049092101     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.04.026     Document Type: Article

References (36)

1. Vaux D.L., and Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci U S A 93 6 (1996) 2239-2244
2. Gross A., McDonnell J.M., and Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13 15 (1999) 1899-1911
3. Letai A., Bassik M., Walensky L., Sorcinelli M., Weiler S., and Korsmeyer S. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2 3 (2002) 183
4. Willis S.N., Fletcher J.I., Kaufmann T., van Delft M.F., Chen L., Czabotar P.E., et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315 5813 (2007) 856-859
5. Danial N.N., and Korsmeyer S.J. Cell death: critical control points. Cell 116 2 (2004) 205-219
6. Vila M., and Przedborski S. Neurological diseases: targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4 5 (2003) 365-375
7. Perier C., Tieu K., Guegan C., Caspersen C., Jackson-Lewis V., Carelli V., et al. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci USA 102 52 (2005) 19126-19131
8. Perier C., Bove J., Wu D.C., Dehay B., Choi D.K., Jackson-Lewis V., et al. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci U S A 104 19 (2007) 8161-8166
9. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 98 5 (2001) 2837-2842
10. Viswanath V., Wu Y., Boonplueang R., Chen S., Stevenson F.F., Yantiri F., et al. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J Neurosci 21 24 (2001) 9519-9528
11. Mochizuki H., Hayakawa H., Migita M., Shibata M., Tanaka R., Suzuki A., et al. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A 98 19 (2001) 10918-10923
12. Hartmann A., Hunot S., Michel P.P., Muriel M.P., Vyas S., Faucheux B.A., et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A 97 6 (2000) 2875-2880
13. Hartmann A., Michel P.P., Troadec J.D., Mouatt-Prigent A., Faucheux B.A., Ruberg M., et al. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?. J Neurochem 76 6 (2001) 1785-1793
14. Tatton N.A. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 166 1 (2000) 29-43
15. Clayton R., Clark J.B., and Sharpe M. Cytochrome c release from rat brain mitochondria is proportional to the mitochondrial functional deficit: implications for apoptosis and neurodegenerative disease. J Neurochem 92 4 (2005) 840-849
16. Green D.R., and Kroemer G. The pathophysiology of mitochondrial cell death. Science 305 5684 (2004) 626-629
17. Kroemer G., and Reed J.C. Mitochondrial control of cell death. Nat Med 6 (2000) 513-519
18. Cassarino D.S., Parks J.K., Parker Jr. W.D., and Bennett Jr. J.P. The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta 1453 1 (1999) 49-62
19. Lotharius J., and O'Malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 275 49 (2000) 38581-38588
20. Parker Jr. W.D., Boyson S.J., and Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26 (1989) 719-723
21. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54 (1990) 823-827
22. Keeney P.M., Xie J., Capaldi R.A., and Bennett Jr. J.P. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26 19 (2006) 5256-5264
23. Wu D.C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A 100 (2003) 6145-6150
24. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52 (1989) 381-389
25. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., and Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A 93 7 (1996) 2696-2701
26. Alam Z.I., Daniel S.E., Lees A.J., Marsden D.C., Jenner P., and Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69 3 (1997) 1326-1329
27. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290 5493 (2000) 985-989
28. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D., et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69 3 (1997) 1196-1203
29. Zhang J., Perry G., Smith M.A., Robertson D., Olson S.J., Graham D.G., et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154 5 (1999) 1423-1429
30. Xia X.G., Harding T., Weller M., Bieneman A., Uney J.B., and Schulz J.B. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 98 18 (2001) 10433-10438
31. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 100 (2003) 5473-5478
32. Hunot S., Vila M., Teismann P., Davis R.J., Hirsch E.C., Przedborski S., et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 101 2 (2004) 665-670
33. Fannjiang Y., Kim C.H., Huganir R.L., Zou S.F., Lindsten T., Thompson C.B., et al. BAK alters neuronal excitability and can switch from anti- to pro-death function during postnatal development. Dev Cell 4 4 (2003) 575-585
34. Sawada M., Hayes P., and Matsuyama S. Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat Cell Biol 5 4 (2003) 352-357
35. Guo B., Zhai D., Cabezas E., Welsh K., Nouraini S., Satterthwait A.C., et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 423 6938 (2003) 456-461
36. Hetz C., Vitte P.A., Bombrun A., Rostovtseva T.K., Montessuit S., Hiver A., et al. Bax channel inhibitors prevent mitochondrion-mediated apoptosis and protect neurons in a model of global brain ischemia. J Biol Chem 280 52 (2005) 42960-42970